IGC Pharma (IGC) Receivables - Other (2011 - 2026)

IGC Pharma (IGC) posted quarterly Receivables - Other of $657000.0 for Q1 2026, down 1.5% quarter-over-quarter from $667000.0 in Q4 2025.

IGC Pharma (IGC) Receivables - Other (2011 - 2026) Analysis & Trends

IGC Pharma (IGC) has reported Receivables - Other for 16 consecutive years, with $657000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables - Other changed N/A year-over-year to $657000.0; the TTM figure through Mar 2026 stood at $657000.0 (up 812.5% YoY), while the FY2026 annual figure was $657000.0, down 3.38% from the prior year.
Receivables - Other eased to $657000.0 in Q1 2026 per IGC's latest filing, from $667000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $951000.0 in Q2 2023 and bottomed at -$311000.0 in Q1 2024.
Historically, Receivables - Other has averaged $593500.0 across 5 years, with a median of $679500.0 in 2024.
Annual changes were most pronounced in 2023 — Receivables - Other jumped 168.64% — and 2024, when it slumped 627.12%.
IGC Pharma's Receivables - Other stood at $751000.0 in 2022, then advanced by 25.97% to $946000.0 in 2023, then slipped by 28.22% to $679000.0 in 2024, then retreated by 1.77% to $667000.0 in 2025, then slipped by 1.5% to $657000.0 in 2026.
Business Quant data shows IGC's Receivables - Other at $657000.0 in Q1 2026, $667000.0 in Q4 2025, and $670000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	IGC Pharma	27.20 Mn	26.94 Mn	-

Download Data